Moleculin Biotech Inc MBRX.OQ MBRX.O is expected to show no change in quarterly revenue when it reports results on August 4 (estimated) for the period ending June 30 2025
LSEG's mean analyst estimate for Moleculin Biotech Inc is for a loss of 36 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Moleculin Biotech Inc is $4.00, about 84.3% above its last closing price of $0.63
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Mar. 31 2025 | -0.53 | -0.55 | -0.69 | Missed | -24.3 |
Dec. 31 2025 | -1.33 | -1.28 | -0.37 | Beat | 70.9 |
Sep. 30 2024 | -2.44 | -2.44 | -2.85 | Missed | -16.8 |
Jun. 30 2024 | -2.43 | -2.51 | -1.70 | Beat | 32.3 |
Mar. 31 2024 | -3.54 | -3.53 | -2.02 | Beat | 42.8 |
Dec. 31 2023 | -2.96 | -3.05 | -5.02 | Missed | -64.6 |
Sep. 30 2023 | -3.51 | -3.55 | -2.85 | Beat | 19.7 |
Jun. 30 2023 | -4.10 | -4.10 | -3.00 | Beat | 26.8 |
This summary was machine generated August 1 at 13:49 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)